• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Photosensitizer-loaded biomimetic platform for multimodal imaging-guided synergistic phototherapy
【24h】

Photosensitizer-loaded biomimetic platform for multimodal imaging-guided synergistic phototherapy

机译：用于多峰影像推导协同光疗法的光敏剂加载的仿生平台

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Photodynamic therapy (PDT) has attracted much attention as a strategy for tumor therapy. However, the insolubility and poor tumor-targeting ability of most photosensitizers (PSs) hinder PDT from further development. Therefore, it is necessary to explore new carriers with good water solubility and biocompatibility to deliver PSs to tumors. Melanin nanoparticles are novel biomimetic nanocarriers with excellent biocompatibility, loading capacity, photothermal therapy (PTT) and magnetic resonance (MR)/photoacoustic (PA) imaging properties. Here we designed polydopamine melanin nanoparticles (PDMNs) as a delivery platform for the photosensitizer Chlorin e6 (PDMN-Ce6) and realized its application as a theranostic agent for tumor therapy. The PDMN-Ce6 exhibited excellent biocompatibility, good water solubility and high loading capability (35.2 wt%) for Ce6. Compared with the free Ce6, PDMN-Ce6 showed higher cellular internalization and superior synergistic phototherapy effects in an in vitro study. An in vivo study indicated that the accumulation of PDMN-Ce6 at tumor sites was 2.8-fold higher than that of free Ce6 at 24 h post-injection, which was beneficial for MR/PA imaging. Moreover, the synergetic therapy significantly inhibited tumor growth, causing tumor necrosis and tumor angiogenesis suppression. These results suggest that our biomimetic and biocompatible platform could improve the delivery of Ce6 to tumors and realize multimodal imaging-guided tumor synergetic phototherapy.
机译：光动力疗法（PDT）吸引了许多关注作为肿瘤治疗的策略。然而，大多数光敏剂（PSS）阻碍PDT的不透明度和差异差的肿瘤靶向能力免于进一步的发展。因此，有必要探索具有良好的水溶性和生物相容性的新载体，以将PSS递送至肿瘤。黑色素纳米粒子是新型仿生纳米载体，具有优异的生物相容性，负载能力，光热疗（PTT）和磁共振（MR）/光声（PA）成像性能。在这里，我们设计了聚二氨基氨基黑色素纳米颗粒（PDMNS）作为光敏剂氯庚烷E6（PDMN-CE6）的递送平台，并实现其作为肿瘤治疗的治疗剂的应用。 PDMN-CE6对于CE6，表现出优异的生物相容性，良好的水溶性和高负载能力（35.2重量％）。与自由CE6相比，PDMN-CE6在体外研究中表现出更高的细胞内化和卓越的协同光疗作用。体内研究表明，肿瘤部位PDMN-CE6的积累比注射后24小时高出2.8倍，对MR / PA成像有益。此外，协同疗法显着抑制肿瘤生长，导致肿瘤坏死和肿瘤血管生成抑制。这些结果表明，我们的仿生和生物相容性平台可以改善CE6的递送至肿瘤，实现多式化成像引导肿瘤协同光疗法。

著录项

  • 来源
    《RSC Advances》 |2018年第56期|共11页
  • 作者

    Tian Ying; Zhao Ying; Liu Wenfei; Liu Ying; Tang Yuxia; Teng Zhaogang; Zhang Chunni; Wang Shouju; Lu Guangming;

  • 作者单位

    Nanjing Univ Sch Med Jinling Hosp Dept Med Imaging Nanjing 210002 Jiangsu Peoples R China;

    Nanjing Univ Sch Med Jinling Hosp Dept Med Imaging Nanjing 210002 Jiangsu Peoples R China;

    Nanjing Med Univ Nanjing Hosp 1 Dept Respirat Nanjing 210000 Jiangsu Peoples R China;

    Nanjing Univ Sch Med Jinling Hosp Dept Med Imaging Nanjing 210002 Jiangsu Peoples R China;

    Nanjing Univ Sch Med Jinling Hosp Dept Med Imaging Nanjing 210002 Jiangsu Peoples R China;

    Nanjing Univ Sch Med Jinling Hosp Dept Med Imaging Nanjing 210002 Jiangsu Peoples R China;

    Nanjing Univ Sch Med Jinling Hosp Dept Med Imaging Nanjing 210002 Jiangsu Peoples R China;

    Nanjing Univ Sch Med Jinling Hosp Dept Med Imaging Nanjing 210002 Jiangsu Peoples R China;

    Nanjing Univ Sch Med Jinling Hosp Dept Med Imaging Nanjing 210002 Jiangsu Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号